Acute Kidney Injury (AKI) – Market Insights, Epidemiology and Market Forecast-2027

Albany, Feb 12, 2019 (Issuewire.com) – Acute Kidney Injury (AKI) – Market Insights, Epidemiology and Market Forecast-2027

The market of Acute Kidney Injury in 7MM was found to be USD 4.3 billion in 2016 and is expected to increase from 2016-2027.

More on StockNewDesk:

Key Benefits

  • This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving Acute Kidney Injury market
  • Organize sales and marketing efforts by identifying the best opportunities for the Acute Kidney Injury market
  • To understand the future market competition in the Acute Kidney Injury

Request for sample pages

According to DelveInsight, a total incident population of Acute Kidney Injury (AKI) in 7 major markets was found to be 1,516,635 in 2016

Currently, there are no targeted pharmacotherapies approved for the treatment of AKI. At present, the therapeutic market size of acute kidney injury is mainly accounted by use of Renal Replacement Therapy (RRT) and off-label drugs which includes various classes such as ACE inhibitors, Angiotensin II-Receptor Blockers (ARBs), Diuretics and Non-Steroidal Anti-Inflammatory Drugs (NSAIDs).

More on StockNewDesk:

Companies covered

  • Angion Biomedica
  • Quark Pharmaceutical
  • AM Pharma
  • Sentien Biotechnologies
  • Ato Bio
  • Thrasos Therapeutics
  • Orion Pharma

And  many others

       Drugs covered

  • BB3
  • QPI1002
  • recAP
  • SBI101
  • Reltecimod
  • THR-184
  • Simdax

And many others

Table of contents

1. Key Insights

2. Acute Kidney Injury Market: Overview at a Glance

3. Acute Kidney Injury (AKI): Disease Background and Overview

4. Epidemiology and Patient Population

5. Country Wise-Epidemiology of Acute Kidney Injury

 

5.1. United States

5.2. EU5

5.3. Germany

5.4. France

5.5. Italy

5.6. Spain

5.7. United Kingdom

5.8. Japan

  • Current Treatment Practices
  • Unmet Needs
  • Emerging Therapies

8.1. Key cross competition- Emerging Therapies

8.2. EA-230: Exponential Biotherapies

8.3. Zemiglo: LG Life Sciences

8.4. bRESCAP: Alloksys

8.5. BB3: Angion Biomedica

8.6. QPI-1002: Quark Pharmaceuticals

8.7. recAP: AM Pharma

8.8. THR-184: Thrasos Therapeutics

8.9. Reltecimod: AtoxBio

  • Acute Kidney Injury: 7 Major Market Analysis
  • Market Outlook by Country

10.1. United States Market Outlook

10.2. United States Market Size

10.3. EU-5 Countries: Market Outlook

10.4. Germany Market Size

10.5. France Market Size

10.6. Italy Market Size

10.7. United Kingdom Market Size

10.8. Spain Market Size

10.9. Japan: Market Outlook

  • Trends in the Cost of Therapies in Acute Kidney Injury
  • Market Drivers
  • Market Barriers
  • DelveInsight Capabilities
  • Appendix

15.1. Report Methodology

  • Disclaimer

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.

Contact us:

Shruti Thakur

[email protected]

+919650213330

Media Contact

Delveinsight Business Reserarch LLP

[email protected]

9193216187

304 S. Jones Blvd #2432, Las Vegas NV 89107

https://www.delveinsight.com/

Source :DelveInsight

This article was originally published by IssueWire. Read the original article here.

Latest on StockNewDesk:

Login

Register | Lost your password?